Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 12/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13404585 | 1.00 | TLR2 (0.50) | TLR2LPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL13404564 | 1.00 | TLR2 (0.50) | TLR2LPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL13404560 | 1.00 | TLR2 (0.50) | TLR2LPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL13404592 | 1.00 | TLR2 (0.50) | TLR2LPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL13404590 | 1.00 | TLR2 (0.50) | TLR2LPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL13404593 | 1.00 | TLR2 (0.50) | TLR2LPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL13404562 | 1.00 | TLR2 (0.50) | TLR2LPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL3243421 | 0.99 | TLR2 (0.49) | TLR2LPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL3243545 | 0.99 | TLR2 (0.49) | TLR2LPAR1LPAR3LPAR2PLA2G2C | |
| SCHEMBL3243426 | 0.99 | TLR2 (0.49) | TLR2LPAR1LPAR3LPAR2PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100055169-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | TLR2 428/4885LPAR1 154/4885LPAR3 169/4885 |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | TLR2 390/4885LPAR1 153/4885LPAR3 88/4885 |
| US-20100055169-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | TLR2 390/4885LPAR1 153/4885LPAR3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.